Telomir Pharmaceuticals (TELO) awards director 50,000 options at $1.34 exercise price
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. reported that director Edward Clouston MacPherson received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, vested immediately, expire on April 16, 2036, and represent 50,000 options held directly after the grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MacPherson Edward Clouston
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 50,000 shares (Direct)
Footnotes (2)
- F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
- F2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.
Key Figures
Stock options granted: 50,000 options
Exercise price: $1.34 per share
Underlying shares: 50,000 shares
+2 more
5 metrics
Stock options granted
50,000 options
Non-qualified stock options granted to director on April 16, 2026
Exercise price
$1.34 per share
Exercise price equal to closing price on April 16, 2026
Underlying shares
50,000 shares
Common stock underlying the granted options
Expiration date
April 16, 2036
Expiration of granted stock options
Post-award option holdings
50,000 options
Total options held directly after the reported grant
Key Terms
Non-Qualified Stock Options (right to buy), exercise price, 2023 Omnibus Incentive Plan
3 terms
Non-Qualified Stock Options (right to buy) financial
"security_title: Non-Qualified Stock Options (right to buy)"
exercise price financial
"The exercise price of the stock options issued to the Reporting Person"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2023 Omnibus Incentive Plan financial
"pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Telomir Pharmaceuticals (TELO) report for Edward Clouston MacPherson?
Director Edward Clouston MacPherson was granted 50,000 non-qualified stock options in Telomir Pharmaceuticals. The options were awarded on April 16, 2026, vested immediately, and give him the right to buy common shares at a fixed exercise price until 2036.
How many Telomir (TELO) stock options were granted and at what exercise price?
The filing shows a grant of 50,000 non-qualified stock options with an exercise price of $1.34 per share. The exercise price equals the closing price of Telomir’s common stock on April 16, 2026, the grant date referenced in the footnotes.
When do the Telomir Pharmaceuticals (TELO) stock options granted to MacPherson expire?
The granted options expire on April 16, 2036. This 10-year term means MacPherson may choose to exercise the options any time before that date, subject to the option terms and his continued eligibility under the company’s plan.
Under which plan were the Telomir (TELO) options granted and when did they vest?
The options were granted under Telomir’s 2023 Omnibus Incentive Plan, as amended and restated. According to the footnotes, all of these options vested immediately upon issuance, so they are fully exercisable from the grant date onward.
Did the Telomir Pharmaceuticals (TELO) Form 4 report any stock sales by MacPherson?
No stock sales were reported; the Form 4 discloses only a grant of 50,000 stock options. There were no purchase or sale transactions in common shares, and the reported activity is a compensation-related acquisition of derivative securities.
What is MacPherson’s Telomir (TELO) option holding after this reported grant?
Following the grant, MacPherson is shown as holding 50,000 stock options directly. This post-transaction amount matches the full size of the April 16, 2026 grant and reflects his reported derivative position in these options after the award.